Genelux Co. (NASDAQ:GNLX) Shares Sold by Miracle Mile Advisors LLC

Miracle Mile Advisors LLC reduced its stake in Genelux Co. (NASDAQ:GNLX) by 37.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,000 shares of the company’s stock after selling 15,000 shares during the period. Miracle Mile Advisors LLC owned approximately 0.07% of Genelux worth $59,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GNLX. XTX Topco Ltd purchased a new stake in Genelux during the 3rd quarter worth about $59,000. Armistice Capital LLC acquired a new position in shares of Genelux during the second quarter worth about $1,755,000. Geode Capital Management LLC increased its stake in shares of Genelux by 39.7% during the third quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock worth $749,000 after buying an additional 89,854 shares during the period. Affinity Asset Advisors LLC acquired a new stake in Genelux in the second quarter valued at approximately $195,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Genelux in the second quarter valued at approximately $56,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Genelux Stock Down 0.8 %

Shares of GNLX opened at $2.46 on Friday. The company has a market capitalization of $84.97 million, a price-to-earnings ratio of -2.59 and a beta of -1.68. Genelux Co. has a 52-week low of $1.60 and a 52-week high of $13.22. The stock has a 50 day moving average price of $2.55 and a 200 day moving average price of $2.43.

Wall Street Analyst Weigh In

GNLX has been the subject of several analyst reports. HC Wainwright lowered their price target on shares of Genelux from $32.00 to $30.00 and set a “buy” rating for the company in a report on Friday, November 15th. Guggenheim initiated coverage on shares of Genelux in a research note on Tuesday, October 29th. They set a “buy” rating and a $8.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $18.25.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.